Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

2018 Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis & Market Forecasts to 2023 - Efforts Towards Patent Protection to Drive ADC Market -

Research and Markets
Posted on: 20 Feb 18

The "Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Global Market Forecasts to 2023" report has been added to's offering.

The Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023.

The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.

Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Market Dynamics


  • Rising Global Cancer Epidemics
  • Advances in Linking Technologies Re-Instills Hope in ADC
  • Efforts towards Patent Protection to Drive ADC Market
  • Increasing Demand for Antibody Drug Conjugates


  • Production Hurdles and Cost
  • Inadequacy of Experienced Manufacturers
  • Regulatory Challenges

Key Topics Covered:

1. Research View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. Global Antibody Drug Conjugates Market Outlook to 2023

5. Commercialized Antibody Drug Conjugates

6. Antibody Drug Conjugates Pipeline Analysis

7. Drivers and Challenges

8. Major Potential Antibody Drug Conjugates in Pipeline

9. Trends and Developments

10. Strategic Alliances in the Global Antibody Drug Conjugates Industry

11. Competitive Assessment

  • Bayer AG
  • Concortis Biotherapeutics
  • F. Hoffman-La Roche Ltd.
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • NBE-Therapeutics
  • Oxford BioTherapeutics
  • Pfizer Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

For more information about this report visit

View source version on

Business Wire

Last updated on: 20/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.